Orthopedic surgery or orthopedics (also spelled orthopaedics) is the branch of surgery concerned with conditions involving the musculoskeletal system. Orthopedic surgeons use both surgical and non-surgical means to treat musculoskeletal trauma, sports injuries, degenerative diseases, infections, tumors, and congenital conditions.
SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced that a journal article titled Extracorporeal Shock Wave Therapy for Nonunion of the Tibia, was published in the March 2010 issue of the Journal of Orthopedic Trauma.
A husband and wife research team has found a way to use the sleeve-like cover on bone to heal serious bone injuries faster and more simply than current methods. And they've developed an artificial sleeve that spurs fast healing when a car wreck, bomb blast or disease leaves too little cover.
biospace med (www.biospacemed.com), an emerging medical technology company based in Paris, and Oldelft Benelux, a renowned specialist in medical diagnostic imaging, announced today the signature of an exclusive distribution agreement of EOS, the world’s first ultra-low-dose 2D|3D imager. The agreement will cover the distribution of EOS for the Benelux area (Belgium, The Netherlands & Luxembourg).
ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.
Admission to a hospital when most of the beds are already full can be deadly for patients, according to a new University of Michigan Health System study showing high occupancy increases the risk of dying in the hospital by 5.6 percent.
Under a $7.1 million grant from the National Institutes of Health, Rush University Medical Center is developing a novel program, called WISHFIT, to help pre-menopausal women reduce visceral fat through a sustained increase in physical activity and reduction in stress.
Implantable Provider Group, a leading provider of implantable device management, announced today that it has secured an investment from Sequoia Capital. The funding will enable IPG to invest in future growth initiatives.
Orthofix International N.V. announced today it has sold the assets of its vascular business, including its AV-Impulse® mechanical compression technology, to Covidien.
Axis Surgical Technologies, Inc., announced today that it has received 510(k) clearance from the Food and Drug Administration to market their C-MOR™ Visualization Device for use in diagnostic and operative arthroscopic and endoscopic procedures. The self-contained portable direct-imaging tool provides illumination and visualization of an interior cavity through either a natural or surgical opening.
biospace med announced today that it has received 510(k) clearance from the FDA to market the Company’s sterEOS 2D/3D workstation for pediatric use in spine applications. The Company’s EOS ultra-low-dose imager previously has been FDA-cleared for use in pediatrics and adults, while sterEOS has previously been FDA-cleared for adult use in spine.
Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.
Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein, promotes cartilage regeneration in a large animal model. The data will be presented by Dr. David M. Rosen on March 6, 2010 at the 56th annual meeting of the ORS in New Orleans, LA.
MedShape Solutions announced today that it is pursuing Phase III SBIR awards and has received preferred vendor status at Veterans Health Administration Hospitals and other Federally funded hospitals for its MORPHIX ™ Shape Memory Suture Anchor.
Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company and Pfizer Inc., was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin.
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).
Kansas Health Institute: "Republicans and Democrats were sharply divided Tuesday over a proposed constitutional amendment that sponsors said would let federal officials know Kansans don't want to be told by the government that they must buy health insurance. On a 12-9, party-line vote, the House Health and Human Services Committee voted to recommend House Concurrent Resolution 5032 favorable for passage.
OrthoDynamix announced today that it has received FDA clearance for its new device, ArthroSteer 3.5mm Ablator, a mono polar electrosurgical device, for general surgical use, including the orthopedic and arthroscopic applications for resection, ablation, excision of soft tissue, hemostasis of blood vessels, and coagulating soft tissue in, but not limited to the knee, shoulder, and primarily the hip.
(U.S. Physical Therapy) The American Physical Therapy Association (APTA) reported on its website (APTA.org) on Friday, February 26, 2010 that “The Centers for Medicare and Medicaid Services (CMS) announced that it will hold claims for the first 10 business days of March. The hold will apply to claims with dates of service of March 1, 2010 through March 12, 2010. Claims with dates of service of January 1, 2010-February 28, 2010 will continue to be paid based on the 0% update approved by Congress.
U.S. Physical Therapy, Inc., a leading national operator of outpatient physical and occupational therapy clinics, has acquired a 70% interest in a five clinic outpatient physical therapy group. The practice presently has more than 58,000 patient visits per year and produces approximately $6.9 million in annual revenue.
Baxter International Inc., a global, diversified healthcare company, and ApaTech, a private equity-backed, U.K.-based orthobiologic products company, today announced a definitive agreement whereby Baxter will acquire all of the outstanding equity of ApaTech for total consideration of up to $330 million.